In the latest trading session, 0.52 million Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares changed hands as the company’s beta touched 1.11. With the company’s most recent per share price at $9.39 changed hands at -$0.69 or -6.88% at last look, the market valuation stands at $622.21M. DNA’s current price is a discount, trading about -688.07% off its 52-week high of $74.00. The share price had its 52-week low at $5.26, which suggests the last value was 43.98% up since then. When we look at Ginkgo Bioworks Holdings Inc’s average trading volume, we note the 10-day average is 1.59 million shares, with the 3-month average coming to 1.19 million.
Analysts gave the Ginkgo Bioworks Holdings Inc (DNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.83. If we narrow down to specifics, the data shows that 2 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended DNA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Ginkgo Bioworks Holdings Inc’s EPS for the current quarter is expected to be 0.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Instantly DNA was in red as seen in intraday trades today. With action -0.47%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -86.12%, with the 5-day performance at -0.47% in the red. However, in the 30-day time frame, Ginkgo Bioworks Holdings Inc (NYSE:DNA) is 42.43% up. Looking at the short shares, we see there were 7.42 million shares sold at short interest cover period of 6.4 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need a downside of -34.14% from its recent market value. According to analyst projections, DNA’s forecast low is 7 with 7 as the target high. To hit the forecast high, the stock’s price needs a 25.45% surge from its current level, while the stock would need to tank 25.45% for it to hit the projected low.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Data shows that the Ginkgo Bioworks Holdings Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -26.69% over the past 6 months, a 35.77% in annual growth rate that is considerably higher than the industry average of 17.20%. Year-over-year growth is forecast to reach -9.45% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 44.43M. 4 analysts are of the opinion that Ginkgo Bioworks Holdings Inc’s revenue for the current quarter will be 44.24M. The company’s revenue for the corresponding quarters a year ago was 34.76M and 37.94M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 27.83%. The estimates for the next quarter sales put growth at 16.60%.
The 2024 estimates are for Ginkgo Bioworks Holdings Inc earnings to increase by 45.22%, but the outlook for the next 5-year period is at 31.20% per year.
DNA Dividends
Ginkgo Bioworks Holdings Inc is expected to release its next quarterly earnings report in January.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.68% of Ginkgo Bioworks Holdings Inc shares while 68.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 73.26%. There are 68.36% institutions holding the Ginkgo Bioworks Holdings Inc stock share, with VIKING GLOBAL INVESTORS LP the top institutional holder. As of 2024-06-30, the company held 7.1383% of the shares, roughly 143.09 million DNA shares worth $47.83 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.9327% or 138.96 million shares worth $46.46 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 1.17 shares estimated at $10.79 million under it, the former controlled 2.59% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.16% of the shares, roughly 526.35 shares worth around $4.86 million.
